Literature DB >> 25550832

Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients.

Jiawen Xu1, Wenlin Yang2, Qiangxiu Wang1, Qinghui Zhang3, Xungeng Li4, Xiaoyan Lin1, Xiuping Liu2, Yejun Qin1.   

Abstract

BACKGROUND: Downregulation of hepatocellular carcinoma related protein 1 (HCRP1) has been reported to be associated with a poor prognosis in a variety of malignant tumors. The purpose of this study was to assess HCRP1 expression in breast cancer and to examine its possible correlation with commonly used prognostic factors, particularly epidermal growth factor receptor (EGFR).
METHODS: Immunohistochemical analysis was performed on tumors from 194 patients with primary breast cancer. HCRP1 expression was analyzed along with major clinicopathological variables.
RESULTS: HCRP1 protein expression was shown to be correlated with age (P = 0.001), histological grade (P = 0.005), tumor progression (P = 0.013), and death (P = 0.001), but not with tumor size, lymph-node metastasis, or Ki67 status. Kaplan-Meier survival curves showed that lower HCRP1 expression was significantly correlated with increased short-term survival (P < 0.001), and both univariate and multivariate analyses revealed that HCRP1, tumor size, lymph-node metastasis, and human epidermal growth factor receptor-2 (HER-2) were independent prognostic factors (all P < 0.05). In addition, low HCRP1 expression was much more frequent in triple negative breast cancer (TNBC; 63.89%) than in luminal (16.95%) and HER-2 overexpression phenotypes (7.5%; P < 0.001), and significant correlations between HCRP1 and survival time were observed for the TNBC group (P < 0.004). Furthermore, an inverse relationship between HCRP1 and EGFR expression was found both for the complete set of all cases (P < 0.001), and for each phenotype analyzed individually (P < 0.05).
CONCLUSION: Our results suggest that HCRP1 may play an important role in EGFR regulation and that its decreased expression is an independent predictor of breast cancer, especially in TNBC patients.

Entities:  

Keywords:  Breast cancer; EGFR; HCRP1; prognostic marker; triple negative breast cancer

Mesh:

Substances:

Year:  2014        PMID: 25550832      PMCID: PMC4270550     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

Review 1.  Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

Authors:  Everett E Vokes; Edward Chu
Journal:  Oncology (Williston Park)       Date:  2006-04       Impact factor: 2.990

2.  Prognostic markers in triple-negative breast cancer.

Authors:  Emad A Rakha; Maysa E El-Sayed; Andrew R Green; Andrew H S Lee; John F Robertson; Ian O Ellis
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

Review 3.  Anti-EGFR therapy in colorectal cancer: how to choose the right patient.

Authors:  F Meriggi; B Di Biasi; C Abeni; A Zaniboni
Journal:  Curr Drug Targets       Date:  2009-10       Impact factor: 3.465

Review 4.  Triple negative breast cancer: unmet medical needs.

Authors:  Sumanta Kumar Pal; Barrett H Childs; Mark Pegram
Journal:  Breast Cancer Res Treat       Date:  2010-12-15       Impact factor: 4.872

5.  EGFR expression and gene copy number in triple-negative breast carcinoma.

Authors:  Berrak Gumuskaya; Murat Alper; Sema Hucumenoglu; Kadri Altundag; Aysegul Uner; Gulnur Guler
Journal:  Cancer Genet Cytogenet       Date:  2010-12

Review 6.  Triple-negative/basal-like breast cancer: review.

Authors:  Emad A Rakha; Ian O Ellis
Journal:  Pathology       Date:  2009-01       Impact factor: 5.306

Review 7.  Pharmacotherapy of triple-negative breast cancer.

Authors:  Cagatay Arslan; Omer Dizdar; Kadri Altundag
Journal:  Expert Opin Pharmacother       Date:  2009-09       Impact factor: 3.889

8.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2007       Impact factor: 5.534

Review 9.  Advances in EGFR-directed therapy in head and neck cancer.

Authors:  Gianmauro Numico; Nicola Silvestris; Elvio Grazioso Russi
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

Review 10.  Triple negative tumours: a critical review.

Authors:  J S Reis-Filho; A N J Tutt
Journal:  Histopathology       Date:  2008-01       Impact factor: 5.087

View more
  6 in total

1.  HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance.

Authors:  Yaming Du; Peng Wang; Hongzhi Sun; Jing Yang; Xianping Lang; Zhongbin Wang; Sheng Zang; Lei Chen; Junjun Ma; Daohan Sun
Journal:  Tumour Biol       Date:  2016-10-13

2.  HCRP1, ID4 and Glypican-3: an optimal panel of biomarkers for diagnosis of hepatocellular carcinoma.

Authors:  Shujian Ge; Dan Wang; Beibei Lv; Shuping Yang; Chunmei Liu; Bin Xu; Chunming Zhao; Yejun Qin; Jiawen Xu
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

3.  HCRP1 downregulation confers poor prognosis and induces chemoresistance through regulation of EGFR-AKT pathway in human gastric cancer.

Authors:  Hao Xu; Zhi-Feng Miao; Zhen-Ning Wang; Ting-Ting Zhao; Ying-Ying Xu; Yong-Xi Song; Jin-Yu Huang; Jun-Yan Zhang; Xing-Yu Liu; Jian-Hua Wu; Hui-Mian Xu
Journal:  Virchows Arch       Date:  2017-09-29       Impact factor: 4.064

4.  HCRP-1 regulates EGFR-AKT-BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer.

Authors:  Feifei Chen; Lei Zhang; Jianqiang Wu; Fuchun Huo; Xin Ren; Junnian Zheng; Dongsheng Pei
Journal:  Cell Death Dis       Date:  2018-12-05       Impact factor: 8.469

5.  The Expression Level of BRCA2 and Its Changes during Chemotherapy in Patients with Different Pathological Types of Mammary Cancer.

Authors:  Yu Huang; Min Luo; Junqing Huang; Shaoxin Huang; Liuxia Wei; Yumei Zhang; Zhiming Zhang
Journal:  Iran J Public Health       Date:  2019-09       Impact factor: 1.429

6.  HCRP-1 regulates cell migration, invasion and angiogenesis via Src/ FAK signaling in human prostate cancer.

Authors:  Feifei Chen; Jianqiang Wu; Jingwei Teng; Wang Li; Junnian Zheng; Jin Bai
Journal:  Int J Biol Sci       Date:  2020-01-01       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.